Article thumbnail

DNA Immunization with Fusion of CTLA-4 to Hepatitis B Virus (HBV) Core Protein Enhanced Th2 Type Responses and Cleared HBV with an Accelerated Kinetic

By Ying Yin, Chunchen Wu, Jingjiao Song, Junzhong Wang, Ejuan Zhang, Hongyan Liu, Dongliang Yang, Xinwen Chen, Mengji Lu and Yang Xu
Topics: Research Article
Publisher: Public Library of Science
OAI identifier: oai:pubmedcentral.nih.gov:3142188
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (1995). A ‘‘quickscore’’ method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas.
  2. (2008). A randomized controlled phase IIb trial of antigen-antibody immunogenic complex therapeutic vaccine in chronic hepatitis B patients.
  3. (2007). Adjuvanting a DNA vaccine with a TLR9 ligand plus Flt3 ligand results in enhanced cellular immunity against the simian immunodeficiency virus.
  4. (2006). An immunocompetent mouse model for the tolerance of human chronic hepatitis B virus infection.
  5. (1987). Antibody production to the nucleocapsid and envelope of the hepatitis B virus primed by a single synthetic T cell site.
  6. (2007). Bicistronic woodchuck hepatitis virus core and gamma interferon DNA vaccine can protect from hepatitis but does not elicit sterilizing antiviral immunity.
  7. (2003). CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection.
  8. (1997). Characterization of T-cell response to woodchuck hepatitis virus core protein and protection of woodchucks from infection by immunization with peptides containing a T-cell epitope.
  9. (2001). Coadministration of gamma interferon with DNA vaccine expressing woodchuck hepatitis virus (WHV) core antigen enhances the specific immune response and protects against WHV infection.
  10. (2002). CpG motifs in bacterial DNA and their immune effects.
  11. (2009). Crossclade neutralizing antibodies against HIV-1 induced in rabbits by focusing the immune response on a neutralizing epitope.
  12. (2005). Current developments in viral DNA vaccines: shall they solve the unsolved?
  13. (2007). DEC-205 receptor on dendritic cells mediates presentation of HIV gag protein to CD8+ T cells in a spectrum of human MHC I haplotypes.
  14. (2010). Dendritic cell targeted HIV gag protein vaccine provides help to a DNA vaccine including mobilization of protective CD8+ T cells.
  15. (1996). DNA immunization induces antibody and cytotoxic T cell responses to hepatitis B core antigen in H-2b mice.
  16. (2001). DNA prime/ canarypox boost-based immunotherapy of chronic hepatitis B virus infection in a chimpanzee.
  17. (2008). DNA vaccines targeting tumor antigens to B7 molecules on antigen-presenting cells induce protective antitumor immunity and delay onset of HER-2/Neu-driven mammary carcinoma.
  18. (1998). DNA-based immunization against hepatitis B: experience with animal models.
  19. (1995). DNAmediated immunization to the hepatitis B surface antigen in mice: aspects of the humoral response mimic hepatitis B viral infection in humans.
  20. (2009). Elimination of immunodominant epitopes from multispecific DNA-based vaccines allows induction of CD8 T cells that have a striking antiviral potential.
  21. (1998). Enhanced responses to a DNA vaccine encoding a fusion antigen that is directed to sites of immune induction.
  22. (2003). Enhancement of gp120-specific immune responses by genetic vaccination with the human immunodeficiency virus type 1 envelope gene fused to the gene coding for soluble CTLA4.
  23. (2008). EpCAM-specific vaccine response by modified antigen and chimeric costimulatory molecule in cynomolgus monkeys.
  24. (2006). Gehring AJ
  25. (2010). HIV gag protein is efficiently cross-presented when targeted with an antibody towards the DEC-205 receptor in Flt3 ligand-mobilized murine DC.
  26. (1999). Immunization of woodchucks with plasmids expressing woodchuck hepatitis virus (WHV) core antigen and surface antigen suppresses WHV infection.
  27. (1993). Immunization with recombinant woodchuck hepatitis virus nucleocapsid antigen or hepatitis B virus nucleocapsid antigen protects woodchucks from woodchuck hepatitis virus infection.
  28. (2005). Immunization with the gene expressing woodchuck hepatitis virus nucleocapsid protein fused to cytotoxic-Tlymphocyte-associated antigen 4 leads to enhanced specific immune responses in mice and woodchucks.
  29. (2006). Immunogenicity of a hepatitis B DNA vaccine administered to chronic HBV carriers.
  30. (1992). Immunosuppression with cyclosporine during the incubation period of experimental woodchuck hepatitis virus infection increases the frequency of chronic infection in adult woodchucks.
  31. (2010). Improved cellular and humoral immune responses in vivo following targeting of HIV Gag to dendritic cells within human anti-human DEC205 monoclonal antibody.
  32. (2000). Increased DNA vaccine delivery and immunogenicity by electroporation in vivo.
  33. (1985). Protection against hepatitis B virus infection by immunization with hepatitis B core antigen.
  34. (2010). Schurich A
  35. (2005). Targeted delivery of the ErbB2/HER2 tumor antigen to professional APCs results in effective antitumor immunity.
  36. (2009). Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice.
  37. (2008). The efficacy of DNA vaccination is enhanced in mice by targeting the encoded protein to dendritic cells.
  38. (2005). Therapeutic vaccination against chronic hepatitis B virus infection.